Status:
TERMINATED
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Lead Sponsor:
Bayer
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable ...
Eligibility Criteria
Inclusion
- Males \> 18 years previously untreated with Androcur.
- No contraindication to Androcur.
Exclusion
- Liver diseases, malignant liver tumours and wasting diseases (except for carcinoma of the prostate). A history of or existing thrombosis or embolism. Severe chronic depression. Hypersensitivity to cyproterone. Cyproterone acetate in previous therapy.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT00919022
Start Date
August 1 2009
End Date
August 1 2011
Last Update
November 1 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Czechia